SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 07:43:59 2024-06-04 EDT | ||
| 24.39 EUR | +1.75% |
|
| Current month | -1.24% | ||
| 1 month | +5.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 24.39 | +1.75% |
| 24-06-03 | 23.97 | -1.24% |
| 24-05-31 | 24.27 | -0.25% |
| 24-05-30 | 24.33 | -0.90% |
| 24-05-29 | 24.55 | +0.45% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 07:43 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ99CL |
| ISIN | DE000VQ99CL2 |
| Date issued | 2021-08-05 |
| Strike | 3,756 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.8 € |
|---|---|
| Lowest since issue | 6.2 € |
| Spread | 0.02 € |
| Spread % | 0.08% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,954
DKK
Average target price
2,464
DKK
Spread / Average Target
+26.13%
- Stock Market
- Certificates
- Certificat
